Lantheus (LNTH) Expected to Release Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $1.24 per share and revenue of $360.07 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.57 EPS. On average, analysts expect Lantheus to post $4.54 EPS for the current fiscal year and $5.61 EPS for the next fiscal year.

Lantheus Price Performance

Lantheus stock opened at $100.80 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $6.58 billion, a P/E ratio of 20.14 and a beta of 0.01. The business has a 50-day moving average of $100.27 and a 200-day moving average of $91.52. Lantheus has a 1 year low of $50.15 and a 1 year high of $111.86.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent analyst reports. CJS Securities downgraded shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Truist Financial cut shares of Lantheus from a “buy” rating to a “hold” rating and lowered their price objective for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. William Blair set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. Brookline Capital Markets cut Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Leerink Partners set a $102.50 price target on Lantheus in a research report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $107.44.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.